Enfusion Current Deferred Revenue from 2010 to 2025

ENFN Stock  USD 11.10  0.01  0.09%   
Enfusion Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to drop to about 2.1 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
2.2 M
Current Value
2.1 M
Quarterly Volatility
2.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 3.6 M, Net Interest Income of 1.8 M or Depreciation And Amortization of 12.1 M, as well as many indicators such as Price To Sales Ratio of 4.47, Dividend Yield of 0.0034 or PTB Ratio of 13.6. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Enfusion over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Enfusion's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Enfusion Current Deferred Revenue Regression Statistics

Arithmetic Mean5,648,906
Geometric Mean5,013,750
Coefficient Of Variation41.56
Mean Deviation2,105,255
Median7,158,000
Standard Deviation2,347,768
Sample Variance5.5T
Range5.3M
R-Value(0.80)
Mean Square Error2.1T
R-Squared0.64
Significance0.0002
Slope(395,475)
Total Sum of Squares82.7T

Enfusion Current Deferred Revenue History

20252.1 M
20242.2 M
20212.4 M
20207.4 M

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 M2.1 M
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.82)
Earnings Share
0.03
Revenue Per Share
2.19
Quarterly Revenue Growth
0.139
Return On Assets
0.0305
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.